Table 1.
Baseline Characteristics of Study Participants
| Characteristic | Participants, No. (%)a | P Value (INSTI vs PI; n = 41)b | ||||
|---|---|---|---|---|---|---|
| PrOD ± RBV for 24 wk | PrOD ± RBV for 12 wk | Total (N = 45) | ||||
| INSTI (n = 21) | HIV-1 PI (n = 15) | INSTI (n = 5) | HIV-1 PI (n = 4) | |||
| Age, years median (IQR), y | 48 (40, 49) | 58 (55, 61) | 50 (49, 54) | 55 (49, 59) | 53 (47, 58) | <.001 |
| Male sexc | 14 (67) | 12 (80) | 4 (80) | 2 (50) | 32 (71) | 1.0 |
| Race/ethnicity | ||||||
| White, non-Hispanic | 5 (24) | 3 (20) | 1 (20) | 2 (50) | 11 (24) | .37 |
| Black, non-Hispanic | 6 (29) | 8 (53) | 3 (60) | 1 (25) | 18 (40) | |
| Hispanic (regardless of race) | 10 (48) | 4 (27) | 1 (20) | 1 (25) | 16 (36) | |
| Weight, median (IQR), kg 2 | 85 (78, 93) | 71 (65, 88) | 86 (84, 99) | 58 (52, 75) | 81 (68, 91) | .007 |
| HCV genotype 1a | 16 (76) | 13 (87) | 5 (100) | 4 (100) | 38 (84) | .42 |
| HCV RNA, median (IQR), log10 IU/mL | 6.5 (6.0, 6.8) | 6.5 (5.8, 7.0) | 5.9 (5.1, 6.3) | 6.2 (5.9, 6.5) | 6.4 (5.8, 6.8) | .84 |
| IL28B rs12979860 | . | |||||
| CC | 3 (14) | 3 (20) | 1 (20) | 2 (50) | 9 (20) | 78 |
| CT | 11 (52) | 8 (53) | 3 (60) | 0 (0) | 22 (49) | |
| TT | 7 (33) | 4 (27) | 1 (20) | 2 (50) | 14 (31) | |
| Cirrhosisd | 6 (29) | 2 (13) | 0 (0) | 0 (0) | 8 (18) | .25 |
| FIB-4 score, median (IQR) | 1.3 (0.8, 2.1) | 1.7 (1.3, 2.3) | 1.3 (1.0, 1.9) | 1.0 (0.6, 1.3) | 1.4 (1.0, 2.2) | .37 |
| HCV treatment naive | 20 (95) | 12 (80) | 5 (100) | 3 (75) | 40 (89) | .16 |
| CD4 T-cell count, median (IQR), cells/µ L | 752 (467, 1064) | 646 (466, 849) | 674 (528, 726) | 525 (404, 683) | 665 (464, 894) | .64 |
| HIV RNA >40 copies/mL | 0 (0) | 1 (7) | 0 (0) | 0 (0) | 1 (2) | .46 |
| Interval between HCV diagnosis and study entry, median (IQR), y | 4.4 (2.8, 14.3) | 16.5 (14.4, 17.7) | 13.7 (11.2, 16.7) | 14.0 (8.8, 19.0) | 14.0 (4.1, 17.4) | <.001 |
Abbreviations: FIB-4, fibrosis 4 index; HCV, hepatitis C virus; HIV-1, human immunodeficiency virus type 1; INSTI, integrase strand-transfer inhibitor; IQR, interquartile range; PI, protease inhibitor; PrOD, paritaprevir-ritonavir-ombitasvir plus dasabuvir; RBV, ribavirin.
aData represent no. (%) of participants unless otherwise identified as median (IQR) values.
bComparisons between subsets of nonrandomized INSTI groups (24- and 12-week cohorts; n = 22) and PI groups (24- and 12-week cohorts; n = 19), who completed PrOD treatment with or without RBV and were responders with a sustained virologic response. P values are based on Fisher exact tests for categorical and Wilcoxon rank sum tests for continuous variables.
cGender identity was not collected for the 24-week cohorts; all 9 participants in the 12-week cohorts self-identified as cisgender.
dCirrhosis status was determined by means of biopsy (n = 1), transient elastography (n = 27), or a combination of peripheral blood markers (FibroSURE test and aspartate aminotransferase–platelet ratio index; n = 17).